Literature DB >> 21730014

Apoptotic role of IKK in T-ALL therapeutic response.

Irene Riz1, Lynnsey A Zweier-Renn, Ian Toma, Teresa S Hawley, Robert G Hawley.   

Abstract

Despite considerable progress in the treatment of T cell acute lymphoblastic leukemia (T-ALL), it is still the highest risk malignancy among ALL. The outcome of relapsed patients remains dismal. The pro-survival role of NOTCH1 and NFκB in T-ALL is well documented; also, both factors were reported to be predictive of relapse. The NOTCH1 signaling pathway, commonly activated in T-ALL, was shown to enhance the transcriptional function of NFκB via several mechanisms. Thus, pharmacological inhibition of NOTCH1-NFκB signaling was suggested to be incorporated into existing T-ALL treatment protocols. However, conventional chemotherapy is based on activation of various types of stress, such as DNA damage, mitotic perturbations or endoplasmic reticulum overload. NFκB is frequently activated in response to stress and, depending on yet unknown mechanisms, it either protects cells from the drug action or mediates apoptosis. Here, we report that T-ALL cells respond to NFκB inhibition in opposite ways depending on whether they were treated with a stress-inducing chemotherapeutic agent or not. Moreover, we found that NOTCH1 enhances NFκB apoptotic function in the stressed cells. The data argue for further studies of NFκB status in T-ALL patients on different treatment protocols and the impact of activating NOTCH1 mutations on treatment response.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21730014      PMCID: PMC3157555          DOI: 10.1158/1541-7786.MCR-11-0109

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  25 in total

Review 1.  Systematic review of the addition of vincristine plus steroid pulses in maintenance treatment for childhood acute lymphoblastic leukaemia - an individual patient data meta-analysis involving 5,659 children.

Authors:  T O B Eden; R Pieters; S Richards
Journal:  Br J Haematol       Date:  2010-03-16       Impact factor: 6.998

2.  Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90.

Authors:  Gesche Tallen; Richard Ratei; Georg Mann; Gertjan Kaspers; Felix Niggli; Alexandr Karachunsky; Wolfram Ebell; Gabriele Escherich; Martin Schrappe; Thomas Klingebiel; Ruediger Fengler; Günter Henze; Arend von Stackelberg
Journal:  J Clin Oncol       Date:  2010-04-12       Impact factor: 44.544

3.  Proteasome inhibitor PS-341 (bortezomib) induces calpain-dependent IkappaB(alpha) degradation.

Authors:  Chunyang Li; Shuzhen Chen; Ping Yue; Xingming Deng; Sagar Lonial; Fadlo R Khuri; Shi-Yong Sun
Journal:  J Biol Chem       Date:  2010-03-24       Impact factor: 5.157

4.  Genetic dissection of c-myc apoptotic pathways.

Authors:  C E Nesbit; J M Tersak; L E Grove; A Drzal; H Choi; E V Prochownik
Journal:  Oncogene       Date:  2000-06-29       Impact factor: 9.867

5.  Gene-based outcome prediction in multiple cohorts of pediatric T-cell acute lymphoblastic leukemia: a Children's Oncology Group study.

Authors:  Amanda L Cleaver; Alex H Beesley; Martin J Firth; Nina C Sturges; Rebecca A O'Leary; Stephen P Hunger; David L Baker; Ursula R Kees
Journal:  Mol Cancer       Date:  2010-05-12       Impact factor: 27.401

6.  Regulation of Vinca alkaloid-induced apoptosis by NF-kappaB/IkappaB pathway in human tumor cells.

Authors:  Yi Huang; Yong Fang; Jinmin Wu; Jennifer M Dziadyk; Xueming Zhu; Meihua Sui; Weimin Fan
Journal:  Mol Cancer Ther       Date:  2004-03       Impact factor: 6.261

7.  The Notch/Hes1 pathway sustains NF-κB activation through CYLD repression in T cell leukemia.

Authors:  Lluis Espinosa; Severine Cathelin; Teresa D'Altri; Thomas Trimarchi; Alexander Statnikov; Jordi Guiu; Veronica Rodilla; Julia Inglés-Esteve; Josep Nomdedeu; Beatriz Bellosillo; Carles Besses; Omar Abdel-Wahab; Nicole Kucine; Shao-Cong Sun; Guangchan Song; Charles C Mullighan; Ross L Levine; Klaus Rajewsky; Iannis Aifantis; Anna Bigas
Journal:  Cancer Cell       Date:  2010-09-14       Impact factor: 31.743

8.  TLX1 and NOTCH coregulate transcription in T cell acute lymphoblastic leukemia cells.

Authors:  Irene Riz; Teresa S Hawley; Truong V Luu; Norman H Lee; Robert G Hawley
Journal:  Mol Cancer       Date:  2010-07-09       Impact factor: 27.401

9.  The favorable effect of activating NOTCH1 receptor mutations on long-term outcome in T-ALL patients treated on the ALL-BFM 2000 protocol can be separated from FBXW7 loss of function.

Authors:  C Kox; M Zimmermann; M Stanulla; S Leible; M Schrappe; W-D Ludwig; R Koehler; G Tolle; O R Bandapalli; S Breit; M U Muckenthaler; A E Kulozik
Journal:  Leukemia       Date:  2010-10-14       Impact factor: 11.528

10.  Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia.

Authors:  C H Pui; D Pei; J T Sandlund; R C Ribeiro; J E Rubnitz; S C Raimondi; M Onciu; D Campana; L E Kun; S Jeha; C Cheng; S C Howard; M L Metzger; D Bhojwani; J R Downing; W E Evans; M V Relling
Journal:  Leukemia       Date:  2009-12-10       Impact factor: 11.528

View more
  3 in total

1.  An Integrated Bioinformatics and Computational Biology Approach Identifies New BH3-Only Protein Candidates.

Authors:  Robert G Hawley; Yuzhong Chen; Irene Riz; Chen Zeng
Journal:  Open Biol J       Date:  2012-05-04

2.  The DN2 Myeloid-T (DN2mt) Progenitor is a Target Cell for Leukemic Transformation by the TLX1 Oncogene.

Authors:  Lynnsey A Zweier-Renn; Irene Riz; Teresa S Hawley; Robert G Hawley
Journal:  J Bone Marrow Res       Date:  2013-02-20

3.  Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-κB.

Authors:  Francesca Buontempo; Ester Orsini; Annalisa Lonetti; Alessandra Cappellini; Francesca Chiarini; Camilla Evangelisti; Cecilia Evangelisti; Fraia Melchionda; Andrea Pession; Alice Bertaina; Franco Locatelli; Jessika Bertacchini; Luca Maria Neri; James A McCubrey; Alberto Maria Martelli
Journal:  Oncotarget       Date:  2016-01-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.